GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (MEX:RARE) » Definitions » Cyclically Adjusted Book per Share

Ultragenyx Pharmaceutical (MEX:RARE) Cyclically Adjusted Book per Share : MXN200.52 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2024 was MXN28.015. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN200.52 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Ultragenyx Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-24), Ultragenyx Pharmaceutical's current stock price is MXN751.98. Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was MXN200.52. Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is 3.75.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 7.39. The lowest was 2.68. And the median was 3.61.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 236.66 194.52

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 217.05 235.29 213.13 194.52 200.52

Competitive Comparison of Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=28.015/131.7762*131.7762
=28.015

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 66.050 100.560 86.554
201409 84.039 100.428 110.272
201412 85.422 99.070 113.623
201503 146.028 99.621 193.162
201506 138.878 100.684 181.765
201509 251.046 100.392 329.529
201512 234.864 99.792 310.139
201603 216.243 100.470 283.623
201606 210.243 101.688 272.451
201609 220.085 101.861 284.721
201612 236.951 101.863 306.535
201703 217.573 102.862 278.732
201706 182.963 103.349 233.289
201709 156.141 104.136 197.585
201712 170.508 104.011 216.024
201803 264.715 105.290 331.307
201806 276.013 106.317 342.109
201809 245.262 106.507 303.452
201812 235.072 105.998 292.241
201903 300.168 107.251 368.809
201906 273.079 108.070 332.983
201909 248.618 108.329 302.429
201912 213.181 108.420 259.105
202003 240.099 108.902 290.532
202006 265.761 108.767 321.981
202009 241.991 109.815 290.385
202012 343.660 109.897 412.079
202103 319.645 111.754 376.912
202106 285.576 114.631 328.288
202109 282.484 115.734 321.639
202112 272.917 117.630 305.739
202203 227.196 121.301 246.816
202206 194.849 125.017 205.384
202209 134.568 125.227 141.606
202212 97.899 125.222 103.023
202303 56.243 127.348 58.199
202306 30.953 128.729 31.686
202309 7.654 129.860 7.767
202312 56.793 129.419 57.827
202403 28.015 131.776 28.015

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Ultragenyx Pharmaceutical  (MEX:RARE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=751.98/200.52
=3.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 7.39. The lowest was 2.68. And the median was 3.61.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (MEX:RARE) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (MEX:RARE) Headlines